AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01368887
Drug: Nicotinamide Monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Trial: NCT00553293
Drug: recombinant follicle stimulating hormone (Gonal-f)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFSH 150 iu/day
Trial: NCT03994484
Drug: HA121-28 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Trial: NCT03994484
Drug: HA121-28 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Trial: NCT02182154
Drug: BIBF 1120 ES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00893971
Drug: PT001 + PT005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled PT001 + PT005, single dose
Trial: NCT02300623
Drug: Antiretroviral therapy alone
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiretroviral therapy
Trial: NCT03530319
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Trial: NCT03530319
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Trial: NCT03813641
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Trial: NCT02314312
Drug: Everolimus + low dose cyclosporin A + prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02314312
Drug: Standard immunosupressive regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02927496
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Trial: NCT02927496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
Trial: NCT02855177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as suspension administered every 8 hours, with food
Trial: NCT02372344
Drug: AZD0585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
Trial: NCT02179749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, Four tablets daily/am for 1-week duration.
Trial: NCT04039321
Drug: ESPB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
Trial: NCT04039321
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
Trial: NCT01538849
Drug: YH4808 A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet = YH4808 A mg
Trial: NCT01538849
Drug: YH4808 B mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet = YH4808 B mg
Trial: NCT01059773
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
Trial: NCT00463840
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00636636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily; 300 mg and 600 mg tablets
Trial: NCT00494221
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00494221
Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01366638
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule taken by mouth once daily for 12 weeks
Trial: NCT00000213
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03934359
Drug: DN1508052-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
Trial: NCT00477204
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg daily
Trial: NCT00477204
Drug: Ezetimibe/Simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10mg)/Simvastatin (20mg)
Trial: NCT04484844
Drug: TOKUYAMA SHIELD FORCE PLUS
RxNorm normalized name: Peroxy Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reinforcing (SR) monomer technology
Trial: NCT01803087
Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03796676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03796676
Drug: PF04965842
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg QD
Trial: NCT01085084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Trial: NCT01733992
Drug: R348 Ophthalmic Solution, 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
Trial: NCT01733992
Drug: R348 Ophthalmic Solution, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
Trial: NCT01733992
Drug: R348 Ophthalmic Solution, 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
Trial: NCT01733992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, single and multiple ascending dose
Trial: NCT04525326
Drug: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Chemotherapy
Trial: NCT02389374
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard dose
Trial: NCT00726258
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological serum
Trial: NCT01204775
Drug: Placebo (Saxagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, 1-16 weeks
Trial: NCT02192853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 4: placebo tablet
Trial: NCT02913105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard Gelatin Capsule
Trial: NCT01172808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that represents comparator
Trial: NCT01172808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that represents BI drug
Trial: NCT01937715
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
Trial: NCT01937715
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose FOLFIRI regimen every 2 weeks
Trial: NCT03671785
Drug: PRIM-DJ2727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
Trial: NCT03671785
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
Trial: NCT02295332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo capsules to RG7625, according to treatment schedule
Trial: NCT02295332
Drug: RG7625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, capsules, single ascending dose according to treatment schedule
Trial: NCT00198523
Drug: Prednisolone and Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00198523
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02815267
Drug: FMX-101, 4% minocycline foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
Trial: NCT03074968
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline application
Trial: NCT02374437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Trial: NCT02290145
Drug: TPF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
Trial: NCT02128334
Drug: Eligard 45 mg Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections
Trial: NCT03099226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo blue hard gelatine capsules
Trial: NCT03099226
Drug: BIA 5-453
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
Trial: NCT02143934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pills, appearance identical to Primaquine tablets
Trial: NCT02143934
Drug: Artemether Lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01648998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00359294
Drug: PM00104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously over 1 hour daily for 5 days, every 3 weeks.
Trial: NCT03811054
Drug: Apatinib（250mg/d） combined with EGFR-TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Trial: NCT04519762
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Trial: NCT04519762
Drug: Inotropes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Trial: NCT00369161
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782754
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02347072
Drug: Spiriva® Respimat® (Tiotropium Bromide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Trial: NCT03579823
Drug: AVT02 100MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
Trial: NCT00275015
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03973697
Drug: Penn Microbiome Therapy - 001
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota for Transplant, enema product
Trial: NCT03973697
Drug: Penn Microbiome Therapy - 003
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota for Transplant, capsule product
Trial: NCT01129271
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01404949
Drug: Tretinoin and Arsenic Trioxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description
Trial: NCT03879252
Drug: Mouthwashes
RxNorm normalized name: MOUTHWASHES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwashes three times a day with a 1.4% baking mouthwash solution.
Trial: NCT02741115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00521885
Drug: Arixtra (Fondaparinox) 2.5 mg SC Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
Trial: NCT00521885
Drug: Lovenox 40mg SC Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
Trial: NCT01615978
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Trial: NCT00033878
Drug: Noni Extract
RxNorm normalized name: noni fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01325571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00502853
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg/week
Trial: NCT00497055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Aripiprazole gel caps.
Trial: NCT01210014
Drug: zinc sulphate 220mg/day in one dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
Trial: NCT01170819
Drug: Dinoprostone 10 mg controlled-release vaginal insert
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
Trial: NCT02867800
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)
Trial: NCT02867800
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight.
Trial: NCT03171740
Drug: Oral saline
RxNorm normalized name: Walgreens Phosphate Oral Saline Laxative SF Solution (Cherry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral saline, 0.25ml/kg
Trial: NCT00960973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02547701
Drug: P-3058
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00927225
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03338244
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
Trial: NCT03338244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
Trial: NCT03970200
Drug: Penn Microbiome Therapy - 001
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota for Transplant, enema product
Trial: NCT03970200
Drug: Penn Microbiome Therapy - 003
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota for Transplant, capsule product
Trial: NCT01422707
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/m2/per day PO at bedtime (X4 weeks)
Trial: NCT02548715
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02548715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01139671
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses.
Trial: NCT02774187
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT01634568
Drug: V81444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo
Trial: NCT02322333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00076999
Drug: TPV oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipranavir oral solution
Trial: NCT00076999
Drug: RTV oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir oral solution
Trial: NCT03780972
Drug: ONL1204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
Trial: NCT00966901
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.